Current Report Filing (8-k)
March 01 2021 - 8:14AM
Edgar (US Regulatory)
0001178879
false
0001178879
2021-03-01
2021-03-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO
SECTION
13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 1, 2021
AMICUS THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of
Incorporation)
Delaware
|
|
001-33497
|
|
71-0869350
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
3675 Market Street, Philadelphia, PA 19104
(Address of Principal Executive Offices,
and Zip Code)
215-921-7600
Registrant’s Telephone Number,
Including Area Code
(Former Name or Former
Address, if Changed Since Last Report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock Par Value $0.01
|
FOLD
|
NASDAQ
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 – Results
of Operations and Financial Condition
On March 1, 2021, Amicus Therapeutics, Inc.
(the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2020.
A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on March 1,
2021 to discuss its full year results of operations. A copy of the conference call presentation materials is attached hereto as
Exhibit 99.2. Both exhibits are incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Current Report on Form 8-K and the Exhibits shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits:
Signature
Page
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMICUS THERAPEUTICS, INC.
|
Date: March 1, 2021
|
By:
|
/s/ Ellen S. Rosenberg
|
|
Name: Ellen S. Rosenberg
|
|
Title: Chief Legal Officer and Corporate Secretary
|
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Sep 2023 to Sep 2024